MARKET

LEXX

LEXX

Lexaria Bioscience Corp
NASDAQ
0.5652
+0.0051
+0.91%
Opening 13:06 05/19 EDT
OPEN
0.5740
PREV CLOSE
0.5601
HIGH
0.5747
LOW
0.5500
VOLUME
38.21K
TURNOVER
--
52 WEEK HIGH
1.550
52 WEEK LOW
0.4600
MARKET CAP
14.01M
P/E (TTM)
-1.1807
1D
5D
1M
3M
1Y
5Y
1D
Lexaria Bioscience announces ethics approval for Human Pilot Study 7
TipRanks · 9h ago
Lexaria Bioscience Receives Ethics Approval For Human GLP-1 Study Comparing Oral DehydraTECH-Semaglutide Formulations To Wegovy, With Dosing Expected To Begin In Mid-June
Benzinga · 9h ago
Lexaria wins ethics board clearance for oral semaglutide human pilot study #7
PUBT · 9h ago
Weekly Report: what happened at LEXX last week (0511-0515)?
Weekly Report · 1d ago
Weekly Report: what happened at LEXX last week (0504-0508)?
Weekly Report · 05/11 09:08
Lexaria CEO says pharma partner extends material transfer agreement through end-2026
PUBT · 05/07 13:25
Lexaria Bioscience provides update on Human Pilot Study #7
TipRanks · 05/05 13:24
Lexaria Bioscience Advances Human Study Of DehydraTECH-Semaglutide Versus Wegovy Tablets
Benzinga · 05/05 13:22
More
About LEXX
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company's patented drug delivery formulation and processing platform technology improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. The Company’s segment includes Intellectual Property, B2B Production, and Research and Development. It is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its focus is the investigation and the incorporation of its DehydraTECH drug delivery technology with glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) to enhance absorption and reduce adverse side effects. The Company operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 48 patents granted and many patents pending worldwide.

Webull offers Lexaria Bioscience Corp stock information, including NASDAQ: LEXX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LEXX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LEXX stock methods without spending real money on the virtual paper trading platform.